Related by context. All words. (Click for frequent words.) 65 BLA filing 65 initiate Phase Ib 65 SUCCEED trial 63 Phase IIIb clinical 63 randomized Phase 2b 63 rALLy trial 62 Phase Ib II 62 Allovectin 7 62 talactoferrin 62 Phase IIB 62 ENRICH trial 62 Phase Ib study 62 tolevamer 61 initiate Phase 2b 61 Solazed 61 Cloretazine ® 61 PRECISE trial 61 OvaRex R 61 initiated Phase Ib 61 oral ridaforolimus 61 Phase 2b trial 61 Urocidin 61 EndoTAG TM -1 60 Phase #/#a trial 60 ruxolitinib 60 Phase IIb clinical trials 60 initiate Phase IIb 60 Phase #b/#a 60 trastuzumab DM1 60 IIb clinical trial 60 multicenter Phase 60 PRECISE Trial 60 Phase lll 60 MOZOBIL 60 deforolimus 60 Phase III 60 omiganan 60 Targretin capsules 59 IMC #B 59 pediatric acute lymphoblastic 59 PANVAC VF 59 IIa trial 59 dose cohort 59 phase IIb clinical 59 ELACYT 59 inhaled AAT 59 INCB# [001] 59 Phase 1b 59 refractory metastatic colorectal cancer 59 Cloretazine R VNP#M 59 phase 2a 59 satraplatin Phase 59 phase IIb study 59 Virulizin R 59 GLP toxicology studies 59 initiate Phase 1b 59 UPLYSO 59 PSMA ADC 59 EOquin TM 59 metastatic renal cell 59 Civacir 59 Camvia 59 confirmatory Phase III 59 iii GTx 59 phase Ib 59 Phase II 58 phase IIa 58 BLA submission 58 NDA submission 58 systemic ALCL 58 phase IIb 58 IND submission 58 Azedra TM 58 BRIM3 58 LBH# 58 UVIDEM 58 phase IIb trial 58 Avastin adjuvant 58 Phase Ib 58 Cimzia TM 58 HGS ETR2 58 AIMM trial 58 maribavir 58 Fast Tracked Phase 58 alvespimycin 58 apaziquone 58 elotuzumab 58 bardoxolone 58 TOCOSOL Paclitaxel 58 multicenter Phase II 58 budesonide foam 58 PREGNANT Study 58 rALLy 58 RIGScan CR 58 GALNS 58 Orathecin 58 EmbraceAC 58 registrational 58 PLK1 SNALP 58 Fodosine 58 Panzem R NCD 57 octreotide implant 57 ponatinib 57 Trofex 57 Phase IIb trial 57 ALN VSP Phase 57 MAGE A3 ASCI 57 OvaRex ® MAb 57 VNP#M 57 vosaroxin 57 Phase IIa trials 57 CIP ISOTRETINOIN 57 Evoltra ® 57 Lenocta 57 Phase 2b clinical 57 registrational trial 57 dalbavancin 57 forodesine 57 Phase III randomized controlled 57 adecatumumab MT# 57 brentuximab vedotin SGN 57 phase IIb III 57 Amoxicillin PULSYS Phase III 57 EFAPROXYN 57 sapacitabine 57 FORTIS M 57 nalbuphine ER 57 IIa trials 57 confirmatory Phase 3 57 ongoing Phase 1b 57 Maximum Tolerated Dose 57 Phase 1a clinical 57 Phase IIb trials 57 IMA# 57 Dacogen injection 57 Corlux 57 Aplidin 57 macitentan 57 Allovectin 7 R 57 PREOS R 57 Phase 1a 57 Phase 2a trial 57 vinflunine 57 antibody MAb 57 MEND CABG II 57 Ketotransdel 57 oral methylnaltrexone 57 ARIKACE ™ 57 Tarceva TM 57 phase IIa clinical 57 Biologic License Application BLA 57 vidofludimus 57 trastuzumab DM1 T DM1 57 denosumab oncology 56 TRISENOX 56 HGS ETR1 56 dose escalation Phase 56 Virulizin ® 56 PRESEPT study 56 Phase III HEAT 56 HuMax CD4 56 Androxal TM 56 Velcade bortezomib 56 Allovectin 7 ® 56 CytoFabTM 56 maximally tolerated dose 56 lintuzumab 56 CLARITY study 56 Phase #b/#a clinical 56 BRIM2 56 hoFH 56 BrachySil TM 56 OvaRex 56 huN# DM1 56 dose escalation 56 SinuNase ™ 56 Kahalalide F 56 IL# PE#QQR 56 StemEx R 56 BCX# 56 Aurexis 56 ANCHOR trial 56 Albuferon Phase 56 Proellex TM 56 Phase IIb clinical 56 Phase III pivotal 56 COMFORT II 56 successfully commercialize Iluvien 56 tramiprosate Alzhemed TM 56 pediatric pontine glioma 56 YONDELIS 56 huC# DM4 56 taxane refractory 56 Genasense ® 56 PEARL SC 56 oral deforolimus 56 bavituximab monotherapy trial 56 glufosfamide 56 Viprinex TM 56 Troxatyl 56 Asentar 56 pharmacokinetic PK study 56 pivotal Phase III 56 Eligard ® 56 RAPTIVA 56 Viramidine 56 ENDEAVOR III 56 Phase 2b study 56 RhuDex ® 56 PDE# inhibitors 56 Amrubicin 56 Amoxicillin PULSYS 56 neratinib 56 Zenvia TM 56 metastatic sarcomas 56 Triapine R 56 Zemplar Capsules 56 TG MV 55 pivotal bioequivalence 55 dosing cohort 55 dacetuzumab 55 axitinib 55 isavuconazole 55 Phase 2b kidney transplant 55 oral picoplatin 55 PMA submission 55 rindopepimut 55 Phase III clinical 55 torezolid phosphate 55 Genz # 55 mg/m2 cohort 55 biliary tract cancer 55 GVAX R 55 clinical pharmacology studies 55 Urocidin TM 55 sBLA 55 ITAX 55 Quinamed 55 OVATURE 55 AP# [003] 55 lorcaserin Phase 55 IMC A# 55 lintuzumab SGN 55 EndoTAGTM 1 55 GetGoal Phase III 55 metastatic hormone refractory 55 Virulizin 55 pomalidomide 55 L BLP# 55 PROSTVAC TM 55 RSD# oral 55 FluINsure 55 fidaxomicin Phase 3 55 Zybrestat 55 randomized multicenter Phase III 55 refractory chronic lymphocytic 55 Phase Ib clinical 55 incyclinide 55 Ophena TM 55 Diamyd ® 55 orBec 55 CRp 55 GVAX ® 55 PRIMO CABG 55 alemtuzumab Campath 55 TACI Ig 55 IND CTA 55 BR.# 55 perifosine KRX 55 evaluable subjects 55 Cimzia ® certolizumab pegol 55 Phenoptin 55 ASA# 55 Vectibix panitumumab 55 Phase IIa trial 55 crofelemer 55 TBC# 55 PrevOnco ™ 55 NEUVENGE 55 HCD# [002] 55 ORENCIA ® 55 Arzerra ofatumumab 55 pralatrexate 55 ORENCIA R 55 Phase III TRIST 55 Marketing Authorisation Application MAA 55 Oglemilast 55 Zavesca r 55 ENDEAVOR IV 55 fidaxomicin Phase 55 PEGPH# 54 GRNVAC1 54 AVOREN 54 enoximone 54 ganetespib 54 palifosfamide 54 RSR# 54 OncoVEX 54 APPRAISE 54 MAA submission 54 heavily pretreated 54 NEBIDO 54 PTK# 54 AERx iDMS 54 NEO3 54 Omigard 54 Advaxis Phase 54 PF # [002] 54 dose escalation phase 54 SYMMETRY trial 54 ixabepilone 54 Somatuline R Depot 54 generation URAT1 inhibitor 54 TOLAMBA 54 relapsed MCL 54 MIST II 54 valopicitabine 54 Cloretazine 54 RhuDex TM 54 Somatuline R Autogel R 54 Alzhemed TM 54 Onconase 54 Benlysta belimumab 54 CytoFab ™ 54 Phase IIb 54 ospemifene 54 goserelin 54 Phase III clinical trials 54 DCCR 54 AQ4N 54 multicenter randomized placebo controlled 54 Solorel 54 romidepsin 54 SNS# T 54 RAPTIVA r 54 ADVANCE PD 54 eniluracil 54 romidepsin novel 54 Biologics License Application 54 MAXY alpha 54 labial herpes 54 Telatinib 54 Onalta ™ 54 confirmatory Phase 54 Prosaptide 54 including eniluracil ADH 54 PROSTVAC VF 54 Canvaxin TM 54 BEMA TM Fentanyl 54 acyclovir Lauriad R 54 Bezielle 54 MyVax 54 omacetaxine mepesuccinate 54 Octreolin 54 preclinical pharmacokinetic 54 Phase #b/#a trial 54 evaluating tivozanib 54 sNDA submission 54 THALOMID 54 multicenter randomized Phase 54 Tarsa oral calcitonin 54 ASONEP 54 GRN#L 54 faropenem 54 Ixempra 54 Plenaxis TM 54 ANTEGREN 54 RESTORE CLI trial 54 glucokinase activator 54 ApoB SNALP 54 Azedra ™ 54 PXD# 54 Zymafos 54 AMD# [002] 54 metastatic CRPC 54 danoprevir 54 generation purine nucleoside 54 Vitaxin 54 enzastaurin 54 platinum refractory 54 galiximab 54 PDE4 inhibitor 54 tanespimycin 54 dose escalation clinical 54 CRMD# 54 Loramyc 54 APF# Phase 54 TASQ 54 Nuvion 54 INTERCEPT platelets 54 BrachySil 54 SNT MC# 54 Reverset 54 concurrent chemoradiation 54 Phase IIb III 54 Wyeth Progenics 54 dextromethorphan quinidine 54 CoFactor 54 PEG SN# 54 ritonavir boosted danoprevir 54 ATryn ® 54 oxymorphone ER 54 ONTAK 54 Phase 1b dose escalation 54 dexanabinol 54 Stimuvax R 54 AVADO 54 evaluating satraplatin 53 BST CarGel R 53 POSIDUR TM 53 preclinical toxicology 53 initiate Phase IIa 53 EOquin 53 Onrigin 53 Phase 2a clinical 53 indiplon capsules 53 Aryplase 53 Dendreon Provenge 53 TASKi2 53 Phase 2a clinical trials 53 ThermoDox R 53 relapsed MM 53 Hedgehog antagonist 53 ATL# [001] 53 Harry Palmin President 53 BEXXAR 53 reslizumab 53 lumiliximab 53 Aflibercept 53 relapsed refractory multiple myeloma 53 iniparib 53 XL# SAR# 53 CAMPATH 53 zileuton CR 53 PEG PAL 53 recurrent GBM 53 CIP TRAMADOL ER 53 AeroLEF TM 53 Phase III registrational 53 crizotinib PF # 53 dirucotide 53 Cethrin 53 Q#IR 53 MDS AML 53 Proxinium TM 53 indibulin 53 amrubicin 53 recurrent herpes labialis 53 LymphoStat B belimumab 53 ONGLYZA ™ 53 acyclovir Lauriad ® 53 WILEX 53 Xcellerated T Cells 53 systemic anaplastic large 53 elacytarabine 53 midstage clinical 53 HspE7 53 tezampanel NGX# 53 GENASIS trial 53 StemEx 53 initiated Phase 1b 53 ILLUMINATE 53 TMC# [002] 53 Plenaxis R 53 refractory AML 53 methylnaltrexone 53 hematological indications 53 PROVENGE ® 53 Degarelix 53 APEX PD 53 MERLIN TIMI 53 ADVEXIN clinical 53 Twinrix 53 Veronate 53 ToGA 53 Ceflatonin 53 Aloxi injection 53 Icatibant 53 Temsirolimus 53 recurrent metastatic 53 COSTAR II 53 NeuVax 53 treatment naive genotype 53 IND enabling 53 Phase III ADT 53 Factor VIIa 53 MKC# MT 53 randomized Phase 53 Tocosol Paclitaxel 53 EDEMA4 53 randomized Phase IIb 53 novel histone deacetylase 53 MVax R 53 Cloretazine R 53 seliciclib CYC# 53 Phase III psoriasis 53 Dextofisopam 53 Insegia 53 samalizumab 53 INCB# [002] 53 tremelimumab 53 Neo Bladder Augment 53 JAK inhibitor 53 RAPTIVA R 53 Pivotal Clinical Trial 53 Phases II 53 CCR5 mAb 53 catheter occlusion 53 rPA anthrax vaccine 53 Omnitarg 53 LymphoStat B TM 53 Canvaxin 53 phase Ib clinical 53 Phase 1b trial 53 Alocrest 53 PFO migraine 53 IMPACT IMmunotherapy 53 Aphthasol R 53 severe hypercholesterolemia 53 Phase Ib IIa clinical 53 Exherin TM 53 OPAXIO 53 EndoTAG 53 valopicitabine NM# 53 trastuzumab emtansine T DM1 53 telomerase inhibitor drug 53 eliglustat tartrate 53 bortezomib Velcade 53 NSABP C 53 Phase Ia 53 AnGes 53 ANDA filings 53 Desmoteplase 53 Shigamabs ® 53 initiate multicenter 53 Provecta 53 MGd 53 dose escalation trial 53 ofatumumab HuMax CD# 53 GOUT 53 opioid induced bowel dysfunction 53 generation PNP inhibitor 53 dermatology biopharmaceutical company 53 LibiGel testosterone gel 53 Thalomid ® 53 TASKi3 53 Shigamabs 53 PROSTVAC ® 53 corticosteroid dexamethasone 52 darinaparsin 52 Vascular Wrap 52 inhaled treprostinil 52 Advagraf 52 belinostat 52 rALLy clinical trial 52 Zenvia ™ 52 Spiegelmer ® 52 VEGF Trap 52 interferon gamma 1b 52 Hectorol R 52 Hepatocellular Carcinoma HCC 52 nonsmall cell lung cancer 52 EVIZON TM squalamine lactate 52 HuMax EGFr 52 SAR# [004] 52 hepatitis B vaccine Heplisav 52 Akt inhibitor 52 IMGN# 52 MVax 52 NSABP B 52 Gestiva TM 52 MVA MUC1 IL2 52 otelixizumab 52 Personalized Immunotherapy 52 OncoVEX GM CSF 52 viral kinetic 52 Evoltra 52 low dose cytarabine 52 CR# vcMMAE 52 LEUKINE 52 cutaneous T cell 52 XL# [003] 52 randomized controlled Phase 52 vemurafenib 52 OncoGel 52 gemcitabine Gemzar ® 52 LibiGel BioSante 52 Thorough QT 52 unblind 52 Pivotal Phase III 52 TroVax ® 52 Matrix Phase 2b 52 mipomersen 52 remission induction 52 placebo controlled Phase 52 pain palliation 52 telomerase therapeutic 52 OMAPRO 52 Pivotal Phase 52 PARTNER Trial 52 HuMax CD# 52 Bicifadine 52 sunitinib malate 52 Oncaspar 52 multicenter phase 52 Orphan Status 52 Phase 2a 52 ONCONASE R 52 mg/m2 dose 52 SVR# 52 photoprotective drug 52 brivaracetam 52 oral treprostinil 52 confirmatory clinical 52 Specifid 52 ofatumumab 52 treatment naïve genotype 52 farletuzumab 52 TKM ApoB 52 EGS# 52 pradefovir 52 CHAMPION PCI 52 radiation sensitizer 52 pancreatic carcinoma 52 AMEVIVE 52 Aplidin R 52 LUMINATE 52 PD LID 52 randomized controlled multicenter 52 sitaxsentan 52 multiple myeloma MM 52 CMV vaccine 52 TYZEKA 52 Aurora kinase inhibitor 52 Omacetaxine 52 ZALBIN 52 compound INCB# 52 oblimersen 52 eltrombopag 52 LEP ETU 52 drug figitumumab 52 balsalazide tablet 52 PREOS 52 ALSYMPCA 52 IMPACT DCM 52 Restanza 52 GVAX 52 Tyzeka Sebivo 52 Tarvacin Anti Cancer 52 XmAb# 52 NO# [002] 52 FOLOTYN 52 Firazyr 52 Allovectin 7 r 52 Trastuzumab DM1 52 SinuNase 52 Phase III ThermoDox 52 Nabi HB Intravenous 52 CINTREDEKIN BESUDOTOX 52 ROTATEQ 52 SEPET TM 52 CLIRS trial 52 Annamycin 52 FavId 52 novel therapeutic antibodies 52 prospectively defined 52 metastatic CRC 52 CUSTOM III 52 Ascend Therapeutics 52 budesonide MMX 52 ZACTIMA 52 Phase IIa clinical 52 Biologics License Application BLA 52 mertansine 52 Glybera R 52 urocortin 2 52 Clevudine 52 Genasense oblimersen sodium Injection 52 Novartis MenB vaccine 52 PROPEL trial 52 Archexin 52 TELINTRA 52 BCIRG 52 Xelox 52 gefitinib Iressa 52 preclinical efficacy 52 durable remissions 52 brain metastases originating 52 Clolar ® 52 trial evaluating Prochymal 52 motesanib diphosphate 52 TransVax ™ 52 Phase Ib IIa 52 mifamurtide 52 MIVI III 52 resminostat 52 Phase 2b 52 Neuvenge 52 hepatocellular cancer 52 histone deacetylase HDAC inhibitor 52 Dacogen decitabine 52 Multiferon R 52 CVac 52 Preos 52 teduglutide 52 lorvotuzumab mertansine 52 Forodesine HCl 52 Azedra 52 placebo controlled Phase III 52 T DM1 52 edifoligide E2F Decoy 52 novel VDA molecule 52 oral prodrug 52 CIMZIA TM 52 PI3K/Akt pathway inhibitor 52 midstage trials 52 TELCYTA 52 Clolar 52 Ereska 52 LibiGel Phase III 52 Decapeptyl 52 VALOR trial 52 clofarabine 52 CHOP chemotherapy 52 RhuDex R 52 JOULFERON 51 ACAPODENE 51 motesanib 51 ZEVALIN ® 51 NDA resubmission 51 Ozarelix 51 iv peramivir 51 JZP 51 paclitaxel poliglumex 51 GENASIS clinical 51 OncoVex 51 Lenocta TM 51 RezularTM 51 LB# [003] 51 apoptosis inducer 51 HoFH 51 aflibercept 51 Apoptone 51 ADAGIO study 51 Phase 2b Clinical Trial 51 MYDICAR ® 51 EMPOWER Study 51 Actimmune ® 51 assessing T DM1 51 XOMA 3AB 51 ularitide 51 FDA approvable letter 51 adjuvant tamoxifen 51 liposomal formulation 51 Somatuline Autogel 51 CLORETAZINE TM VNP#M 51 zanolimumab 51 Phase 2a preventative 51 Dose escalation 51 Flutiform ™ 51 haematologic 51 registrational trials 51 PNP inhibitor 51 Sulonex TM 51 IIa clinical trial 51 PrevOnco 51 BRAF mutant 51 Pemetrexed 51 DCVax ® Brain 51 Xanafide 51 Phase 2b clinical trials 51 APTIVUS 51 metastatic castrate resistant 51 AVINZA 51 Heplisav 51 RG# [001] 51 rhThrombin 51 NSCL cancer 51 AzaSite Plus 51 HER2 positive metastatic breast 51 GLP1 agonist 51 bicifadine 51 mRCC 51 DIFICID ™ 51 Biological License Application 51 Taxotere docetaxel 51 im peramivir 51 Phase IIA 51 Neuradiab 51 Raptiva ® 51 Phase IIIb 51 IV acetaminophen 51 clevudine 51 Phase III Pivotal 51 Phase Ia Ib 51 HyperAcute 51 Phase III ALLEGRO 51 blinatumomab 51 Bioral Amphotericin B 51 sunitinib Sutent 51 Junovan 51 NV1FGF 51 Fibrillex TM 51 HCV polymerase 51 Prostate AdenoCarcinoma Treatment 51 OPAXIO TM 51 E1 INT TM 51 VALSTAR TM 51 miconazole MBT 51 cisplatin vinorelbine 51 recurrent glioblastoma 51 QNEXA 51 DR Cysteamine 51 refractory CLL 51 metastatic bladder 51 cetuximab Erbitux 51 Alequel ™ 51 Chemophase 51 tesmilifene 51 AKT inhibitor 51 PRESEPT 51 oral PTH 51 Loramyc R 51 REOLYSIN ® 51 rhIGF-I/rhIGFBP-3 51 KSP inhibitor 51 voreloxin 51 clinical trial 51 Initiate Clinical Trial 51 recurrent malignant glioma 51 Tolamba 51 GRN# 51 AMD# [003] 51 OXi# 51 #mg dosing group 51 M Vax 51 Zerenex 51 phase IIIb 51 ® natalizumab 51 Phase III trials 51 unresectable stage 51 dosing cohorts 51 relapsed multiple myeloma 51 tosedostat 51 undetectable HBV DNA 51 orally administered inhibitor 51 HGS# 51 Trofex TM 51 telaprevir dosing 51 Urocortin 2 51 Oxypurinol 51 nab paclitaxel 51 Phase IIB clinical 51 IIIA NSCLC 51 PEG IFN 51 Lupuzor 51 GV# [001] 51 EDEMA3 51 alvimopan 51 resectable pancreatic cancer 51 DSMB recommended 51 Files Investigational 51 OPT CHF 51 pivotal Phase 51 Preotact 51 investigational antiplatelet agent 51 candidates Dyloject TM 51 BAY #-# 51 Phase IIa clinical trials 51 Preotact R 51 CIMZIA TM certolizumab pegol 51 CLIRS 51 Phase Ib clinical trials 51 R sorafenib tablets 51 MGCD# [001] 51 unblinding 51 Targretin 51 Prestara 51 apricitabine ATC 51 panitumumab 51 Talotrexin 51 Arimidex anastrozole 51 R#/MEM # 51 Oncoscience AG 51 zalutumumab 51 Immunotherapeutic 51 pharmacokinetic PK 51 exploratory Phase IIa 51 FlutiformTM 51 GVAX immunotherapy 51 pertuzumab 51 OraTest R 51 iclaprim 51 Alferon N 51 Excellagen 51 Exelixis XL# 51 DCVax R Brain 51 relapsed AML 51 MoxDuo IR 51 TheraCIM 51 ANYARA 51 Phase 1b clinical 51 3 registrational trial 51 MET inhibitor 51 DEB# 51 Initiate Phase 51 phase III isavuconazole 51 NSABP 51 FOLOTYN ® 51 fund BioSante LibiGel 51 antibiotic telavancin 51 ocrelizumab 51 Capesaris 51 cMET inhibitor 51 Loramyc ® 51 Zenvia Phase III 51 Oncotype DX colon cancer 51 pharmacodynamic PD 51 Loramyc ™ 50 HQK 50 Erbitux cetuximab 50 SCIB1 50 SILENOR TM 50 pixantrone NDA 50 Soliris TM eculizumab 50 adjuvant colon cancer 50 Peginterferon alfa 2b 50 Phase #/#a 50 FLUVIRIN vaccine 50 Vfend 50 PIX# trial 50 Certican 50 epigenetic therapies 50 Saforis 50 Cleviprex TM clevidipine 50 VP# [004] 50 LymphoStat B Phase 50 HCV RESPOND 2 50 Fentanyl TAIFUN R 50 OrCel ® 50 evaluating Actimmune 50 YERVOY 50 PSN# [002] 50 Memryte 50 Phase 2b monotherapy 50 HDL Selective Delipidation 50 mapatumumab 50 Onco TCS 50 Asentar TM 50 Evoltra R 50 lenalidomide dexamethasone 50 sumatriptan injection 50 BioNumerik 50 metastatic HRPC 50 Marqibo 50 LymphoStat B 50 NADiA ProsVue 50 antiangiogenic therapy 50 Anturol TM 50 DAC HYP 50 EINSTEIN DVT 50 elagolix 50 Insulin PH# 50 AZX# Phase 50 oral RELISTOR 50 investigational monoclonal antibody 50 subcutaneous methylnaltrexone 50 Phase III LibiGel 50 JunJing III 50 Viprinex 50 Stedivaze 50 Vertex Pharma 50 AEG# 50 posaconazole 50 eritoran 50 docetaxel Taxotere R 50 Thrombin 50 controlled multicenter Phase 50 non nucleoside inhibitor 50 synDNA TM 50 Trovax 50 celgosivir 50 efficacy endpoint 50 vinorelbine tartrate 50 MAb therapy 50 SinuNase TM 50 JZP 6 50 GED aPC 50 tesetaxel 50 multiple ascending dose 50 ZYBRESTAT 50 Phase III confirmatory 50 Surfaxin LS 50 nucleotide analog 50 MYDICAR 50 SPRYCEL ® 50 polycythemia vera essential thrombocythemia 50 induced macular edema 50 Vicinium TM